🇺🇸 Trastuzumab Emtansine (T-DM1) in United States

4 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 20 April 2025 – 20 April 2026
• Total reports: 4

Most-reported reactions

1. Bundle Branch Block Left — 1 report (25%)
2. Cardiac Failure — 1 report (25%)
3. Cardiotoxicity — 1 report (25%)
4. Left Ventricular Dysfunction — 1 report (25%)

Source database →

Frequently asked questions

Is Trastuzumab Emtansine (T-DM1) approved in United States?

Trastuzumab Emtansine (T-DM1) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Trastuzumab Emtansine (T-DM1) in United States?

Pfizer Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.